Title |
Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies
|
---|---|
Published in |
BMC Cancer, November 2016
|
DOI | 10.1186/s12885-016-2952-3 |
Pubmed ID | |
Authors |
ShengFa Su, YinXiang Hu, WeiWei Ouyang, Zhu Ma, QingSong Li, HuiQin Li, Yu Wang, XiaoHu Wang, Tao Li, JianCheng Li, Ming Chen, You Lu, YuJu Bai, ZhiXu He, Bing Lu |
Abstract |
The role of radiation therapy in addition to chemotherapy has not been well established in non-oligometastatic Stage IV non-small cell lung cancer (NSCLC). We aimed to investigate overall survival (OS) of non-oligometastatic Stage IV NSCLC treated with chemotherapy with concurrent radiation to the primary tumor. Eligible patients were screened from two prospective studies. Oligometastatic and non-oligometastatic NSCLC were defined as having < 5 and ≥5 metastatic lesions, respectively. Prognostic factors for OS were identified by using univariate and multivariate analysis. Landmark analysis and propensity-score matching (PSM) were each performed to further adjust for confounding. A total of 274 patients were identified as the study cohort: 183 had non-oligometastatic disease. For all 274 patients, those who received a radiation dose ≥63 Gy to the primary tumor and had oligometastatic disease had better OS (P < 0.001 and P = 0.017, respectively). When patients were subdivided into those with oligometastatic or non-oligometastatic disease, a radiation dose ≥ 63 Gy remained a significant prognostic factor for better OS. For non-oligometastatic patients, multivariate analysis showed that receiving ≥63 Gy radiation, having a GTV <146 cm(3), having response to chemotherapy, and having stable or increased post-treatment KPS independently predicted better OS (P = 0.018, P = 0.014, P = 0.014, and P = 0.001). After PSM in non-oligometastatic patients, a higher radiation dose (≥63 Gy) remained to be correlated with better OS. By landmark analysis, aggressive radiation (≥63 Gy) remained to be correlated with better OS in Pre-PSM cohort (P = 0.005) and Post-PSM cohort (P = 0.004). Radiation dose, primary tumor volume, response to chemotherapy and KPS after treatment are associated with OS in patients with non-oligometastatic disease; on basis of effective system chemotherapy, aggressive thoracic radiotherapy may prolong OS. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 6% |
Unknown | 16 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 2 | 12% |
Student > Bachelor | 2 | 12% |
Lecturer > Senior Lecturer | 1 | 6% |
Other | 1 | 6% |
Lecturer | 1 | 6% |
Other | 2 | 12% |
Unknown | 8 | 47% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 6 | 35% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
Agricultural and Biological Sciences | 1 | 6% |
Nursing and Health Professions | 1 | 6% |
Unknown | 8 | 47% |